Loading
HKSEHealthcareMedical - Care Facilities
Latest quote
HK$7.17
−HK$0.005 · -0.07%
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
Latest quote
HK$7.17
−HK$0.005 · -0.07%
Regular session · HKT · Market data may be delayed.
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
Day range
Current HK$7.17
52-week range
Current HK$7.17
Regular session · HKT · Market data may be delayed.
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
Day range
Current HK$7.17
52-week range
Current HK$7.17
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 247.15M CNY | 151.3M CNY | 145.73M CNY | 237.19M CNY | 203.22M CNY |
| Cost of goods sold | 129.79M CNY | 63M CNY | 64M CNY | 70.51M CNY | 56.98M CNY |
| Gross profit | 117.36M CNY | 88.3M CNY | 81.72M CNY | 166.68M CNY | 146.24M CNY |
| Research and development | 17.29M CNY | 24.73M CNY | 19.44M CNY | 11.41M CNY | 4.45M CNY |
| Selling, general, and administrative | 61.65M CNY | 75.21M CNY | 77.79M CNY | 25.62M CNY | 20.58M CNY |
| Operating expenses | 78.24M CNY | 69.77M CNY | 76.92M CNY | 45.32M CNY | 36.87M CNY |
| Interest income | 6.79M CNY | 722K CNY | 1.39M CNY | 269K CNY | 344K CNY |
| Interest expense | 1.33M CNY | 1.12M CNY | 719K CNY | 6.91M CNY | 16.55M CNY |
| Depreciation and amortization | 15.49M CNY | 15.12M CNY | 15.28M CNY | 13.87M CNY | 14.04M CNY |
| Operating income | 39.13M CNY | 18.53M CNY | 2.53M CNY | 106.19M CNY | 110.63M CNY |
| Net income | 26.32M CNY | 30.04M CNY | −17.62M CNY | 79.02M CNY | 79.1M CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
